Phase I Open-label, Parallel-group, Comparative Study to Evaluate the Effects of Renal or Hepatic Impairment on TAK-272 Pharmacokinetics With a Single Oral Administration of TAK-272 in Patients With Renal or Hepatic Impairment
Phase of Trial: Phase I
Latest Information Update: 08 Nov 2017
At a glance
- Drugs Imarikiren (Primary)
- Indications Diabetic nephropathies; Hypertension
- Focus Pharmacokinetics
- Sponsors Takeda
- 05 Jul 2016 Status changed from active, no longer recruiting to completed.
- 29 Jun 2016 Status changed from recruiting to active, no longer recruiting.
- 22 Mar 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.